Further research is necessary to elucidate the precise mechanisms by which GPR30 and the PI3K/Akt pathway interact to modulate the effects of an HFD and to determine how these pathways can be targeted for therapeutic interventions in metabolic disorders. The gene discussed is GPER1; the disease is metabolic disease.